[Read](/names) · [Unpick](/preparations) · [Carry](/borders)

[Peptide Int](/)

# A name can cross a border while its approval stays put.

Approved where, and for what? Those are the words I add when an approval claim arrives without much explanation. A medicine’s story in another country can be interesting without becoming an answer for a U.S. reader.

Permission in a particular place

## Authorisation

![A quiet Italian street recedes between warm plaster facades and pale stone paving.](/int-continuation-3dce088ccebe/italian-civic-street.webp)

Italy is the country in this thymosin alpha-1 authorisation example.

Thymosin alpha-1 is a peptide involved in the immune system’s signals. Its man-made version, with the same amino-acid sequence, is called thymalfasin. FDA’s [review describes its foreign authorisations and lack of U.S. approval](https://www.fda.gov/media/183820/download). In Italy, its authorised use is an add-on to flu vaccination for people with weakened immune systems.

That’s more specific than approved overseas. The review also describes injection-site soreness in studies and concerns about ingredient quality and immune reactions. The body may respond to an injected peptide as something foreign. A different preparation needs its own safety explanation.

Semax offers another example. FDA’s [2026 review describes Russian registration as nasal drops](https://www.fda.gov/media/193348/download). It isn’t FDA-approved, and FDA found too little information to establish its safety in people. I keep the country, form and safety limits together.

A foreign authorisation leaves the U.S. access question open.

A process with ingredient rules

## Compounding

Compounding means preparing a medicine under a separate set of rules. In the U.S., 503A generally concerns a preparation for an individual with a prescription; 503B concerns registered outsourcing facilities. These are sections of law. FDA’s [compounding explanation](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) also makes clear that compounded drugs aren’t FDA-approved.

A prescription doesn’t make every starting ingredient eligible. FDA’s [bulk-ingredient rules](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act) set conditions for what can be used. Bulk ingredient just means the starting drug substance. A clinician’s assessment and those ingredient rules both matter.

On FDA’s page current as of April 22, 2026, BPC-157, epitalon, semax, selank and thymosin alpha-1 appear among [nominations that were withdrawn](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks). Withdrawal isn’t clearance, Category 1 placement or approval for compounding. FDA keeps its safety concerns beside the entries and gives no individual move dates.

A research label adds another word to unpack.

A description that cannot supply approval

## Research

Research use only doesn’t turn a substance into an approved medicine. FDA’s [warning about unapproved peptide drugs](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) explains that research wording doesn’t excuse marketing them for human use. The label can’t supply the missing approval or safety evidence.

A [2021 review describes selank as poorly studied](https://pubmed.ncbi.nlm.nih.gov/34396551/); it has no FDA approval. Neither do [epitalon](https://www.fda.gov/media/193345/download) or [BPC-157](https://www.fda.gov/media/193343/download), whose human safety evidence remains inadequate. A name travelling between countries doesn’t resolve those gaps.

For a personal U.S. medical question, a licensed clinician can assess appropriate options, in person or through suitable telehealth, including approved medicines where they exist. I explain the words around that conversation. Athletes also have a separate set of [sport rules](/sport) to consider.

Sport has its own rules to add to the conversation.

Peptide Int is my guide to peptide language; it is not a clinic, a pharmacy or a seller.

[References](/references) · [Sport](/sport) · [About](/about) · [Contact](/contact)

© 2026 Peptide Int